COLD + SINUS TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
01-09-2020
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Beschikbaar vanaf:
VITA HEALTH PRODUCTS INC
ATC-code:
M01AE51
INN (Algemene Internationale Benaming):
IBUPROFEN, COMBINATIONS
Dosering:
200MG; 30MG
farmaceutische vorm:
TABLET
Samenstelling:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
Toedieningsweg:
ORAL
Eenheden in pakket:
10/20/40/50/72/96/100
Prescription-type:
OTC
Therapeutisch gebied:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0222394001; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2010-06-08
Productkenmerken
Vita Health Products Inc.
Page 1
of 49
PRODUCT MONOGRAPH
COLD + SINUS
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
September 1, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control No. 242681
Vita Health Products Inc.
Page 2
of 49
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION....................................................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.....................................................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................................................
5
ADVERSE REACTIONS
...................................................................................................................................
11
DRUG INTERACTIONS
....................................................................................................................................
18
DOSAGE AND ADMINISTRATION
................................................................................................................
21
OVERDOSAGE
..................................................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................................
24
STORAGE AND STABILITY
...........................................................................................................................
28
SPECIAL HANDLING INSTRUCTION
..
Lees het volledige document
